Evidence map›Paper›PMID 31129889›Full record

Trial reportInternational journal of clinical pharmacy2019

Early pharmacokinetics of low dosage mycophenolate exposure in Thai kidney transplant recipients.

Busaya Kulabusaya, Somratai Vadcharavivad, Yingyos Avihingsanon, Teun van Gelder, Kearkiat Praditpornsilpa

Abstract readClinical Trial
PubMed Publisher
In one paragraph

Trial report in International journal of clinical pharmacy, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed, 2 pooled it
0.6field-weighted citation impact, top 37% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 2 syntheses or guidelines pooled it, 5 citations in OpenAlex.

  1. Guideline
  2. Pooled it
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 2 countries.

Busaya KulabusayaDepartment of Pharmacy Practice, Faculty of Pharmaceutical Sciences, Chulalongkorn University, Bangkok, 10330, Thailand.
Somratai VadcharavivadDepartment of Pharmacy Practice, Faculty of Pharmaceutical Sciences, Chulalongkorn University, Bangkok, 10330, Thailand. somratai@gmail.com.ORCID http://orcid.org/0000-0001-5080-7070
Yingyos AvihingsanonDepartment of Medicine, Renal Immunology and Therapeutic Apheresis Research Unit, Faculty of Medicine, Chulalongkorn University, Bangkok, 10330, Thailand.
Teun van GelderDepartment of Hospital Pharmacy, Erasmus Medical Center, Rotterdam, The Netherlands.
Kearkiat PraditpornsilpaDepartment of Medicine, Faculty of Medicine, Chulalongkorn University, Bangkok, 10330, Thailand.
Chulalongkorn University · THErasmus MC · NLSiriraj Hospital · TH

Funding

the Faculty of Pharmaceutical Sciences, Chulalongkorn University, Bangkok, Thailand Phar2560-RG06
6 · The paper itself

Abstract

Background The effects of mycophenolic acid exposure in the early period after transplantation on clinical outcomes have been reported; however, mycophenolic acid exposure in the early period after transplantation in Asian kidney transplant recipients who receive 1.5 g/d mycophenolate mofetil has never been investigated. Objective To determine mycophenolic acid exposure on day 3 post-transplantation in kidney transplant recipiens who receive 1.5 g/d mycophenolate mofetil. The effects of the reduced renal function on mycophenolic acid area under the concentration-time curve (AUC) and the achievement of the target AUC on the incidence of biopsy proven acute rejection during the first month post-transplantation were also evaluated. Setting A university hospital Method Blood samples and 24-h urine were collected on day 3 post-transplantation. Main outcome measures The mycophenolic acid AUC was calculated by linear trapezoidal rule and compared with the target of 45 mg*h/L. Results Of 42 Thai kidney transplant recipiens, the mean mycophenolic acid AUC of 45.1 mg*h/L (SD 14.7) was comparable to the AUC target (P = 0.962). Significant differences of the mycophenolic acid AUC were observed between patients with urine output of < 2400 mL and those with urine output ≥ 2400 mL (35.3 ± 6.6 and 47.4 ± 15.2, respectively; P = 0.002), and between patients with 24-h measured CrCl < 25 mL/min and those with CrCl ≥ 25 mL/min (38.0 (29.0, 42.2) and 49.2 ± 14.0, respectively; P = 0.017). Proportions of overall biopsy proven acute rejection among patients with mycophenolic acid AUC of < 45 and ≥ 45 mg*h/L were comparable (20.0% and 23.5%, respectively; P = 1.000). Conclusions After the starting dosage of 1.5 g/d mycophenolate mofetil, the mean mycophenolic acid AUC on day 3 post-kidney transplantation is comparable with the target of 45 mg*h/L. Severely reduced renal function significantly influences mycophenolic acid exposure.

Indexed as

AdolescentAdultEnzyme InhibitorsFemaleGraft RejectionHumansKidney TransplantationMaleMiddle AgedMycophenolic AcidThailandTransplant RecipientsYoung AdultEnzyme InhibitorsMycophenolic AcidKidney transplantationMycophenolate mofetilMycophenolic acidPharmacokineticsRenal function

Identifiers

PMID31129889
OpenAlexW2946378692

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.